A killer choice for cancer immunotherapy
- PMID: 24791943
- DOI: 10.1007/s12026-014-8507-2
A killer choice for cancer immunotherapy
Abstract
The promise of cell-based immunotherapies for the treatment of cancer offers the potential of therapeutic synergy with chemo- and radiotherapies that may overcome current limitations leading to durable responses and prevention of recurrence. There is a wide array of cell-based immunotherapies that are either poised to enter cancer clinical trials or are in clinical trials, and many are showing some success. Yet within this field, there are clear obstacles that need to be overcome, including limited access across tissue barriers, development of antigen tolerance, and the immunosuppressive microenvironment of tumors. Through an understanding of immune cell signaling and trafficking, immune cell populations can be selected for adoptive transfer, and delivery strategies can be developed that circumvent these obstacles to effectively direct populations of cells with robust anti-tumor efficacy to the target. Within the realm of immune cell therapies, cytokine-induced killer (CIK) cells have demonstrated promising trafficking patterns, effective delivery of synergistic therapeutics, and stand-alone efficacy. Here, we discuss the next generation of CIK therapies and their application for the effective treatment of a wide variety of cancers.
Similar articles
-
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives.Immunotherapy. 2015;7(9):999-1010. doi: 10.2217/imt.15.61. Epub 2015 Aug 27. Immunotherapy. 2015. PMID: 26310715 Review.
-
The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.Hum Immunol. 2015 May;76(5):385-91. doi: 10.1016/j.humimm.2014.09.021. Epub 2014 Oct 8. Hum Immunol. 2015. PMID: 25305457 Review.
-
Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy.J Cell Physiol. 2020 Dec;235(12):9291-9303. doi: 10.1002/jcp.29827. Epub 2020 Jun 2. J Cell Physiol. 2020. PMID: 32484595 Review.
-
The Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors.Technol Cancer Res Treat. 2017 Oct;16(5):577-585. doi: 10.1177/1533034616659163. Epub 2016 Jul 19. Technol Cancer Res Treat. 2017. PMID: 27436839 Free PMC article.
-
DC-CIK as a widely applicable cancer immunotherapy.Expert Opin Biol Ther. 2020 Jun;20(6):601-607. doi: 10.1080/14712598.2020.1728250. Epub 2020 Feb 13. Expert Opin Biol Ther. 2020. PMID: 32033522 Review.
Cited by
-
Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.Front Immunol. 2017 Jul 6;8:774. doi: 10.3389/fimmu.2017.00774. eCollection 2017. Front Immunol. 2017. PMID: 28729866 Free PMC article. Review.
-
Cancer Immunotherapy with Cytokine-Induced Killer Cells.Target Oncol. 2017 Jun;12(3):289-299. doi: 10.1007/s11523-017-0489-2. Target Oncol. 2017. PMID: 28474278 Review.
-
Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition.Oncoimmunology. 2015 Aug 31;5(3):e1086060. doi: 10.1080/2162402X.2015.1086060. eCollection 2016 Mar. Oncoimmunology. 2015. PMID: 27141341 Free PMC article.
-
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.Int J Mol Sci. 2021 May 28;22(11):5801. doi: 10.3390/ijms22115801. Int J Mol Sci. 2021. PMID: 34071550 Free PMC article. Review.
-
Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition.Oncotarget. 2015 Oct 27;6(33):35023-39. doi: 10.18632/oncotarget.5280. Oncotarget. 2015. PMID: 26418951 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources